Edwards Lifesciences Corp (EW) VP Larry L. Wood Sells 6,300 Shares

Edwards Lifesciences Corp (NYSE:EW) VP Larry L. Wood sold 6,300 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $121.00, for a total value of $762,300.00. Following the transaction, the vice president now owns 116,148 shares of the company’s stock, valued at $14,053,908. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Larry L. Wood also recently made the following trade(s):

  • On Friday, December 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences stock. The shares were sold at an average price of $114.58, for a total value of $2,172,436.80.
  • On Wednesday, November 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences stock. The shares were sold at an average price of $104.76, for a total value of $1,986,249.60.

Shares of Edwards Lifesciences Corp (NYSE EW) opened at $120.49 on Thursday. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33. Edwards Lifesciences Corp has a 12-month low of $86.55 and a 12-month high of $122.93. The company has a market capitalization of $25,500.00, a price-to-earnings ratio of 35.03, a P/E/G ratio of 1.92 and a beta of 0.51.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The business had revenue of $821.50 million for the quarter, compared to analysts’ expectations of $833.85 million. During the same period last year, the business earned $0.68 earnings per share. The company’s quarterly revenue was up 11.1% on a year-over-year basis. research analysts predict that Edwards Lifesciences Corp will post 3.76 EPS for the current fiscal year.

Edwards Lifesciences declared that its Board of Directors has initiated a stock repurchase program on Thursday, December 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

A number of large investors have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. boosted its position in Edwards Lifesciences by 4.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 723,832 shares of the medical research company’s stock worth $81,584,000 after purchasing an additional 28,821 shares during the last quarter. First National Trust Co boosted its position in Edwards Lifesciences by 77.8% in the fourth quarter. First National Trust Co now owns 16,298 shares of the medical research company’s stock worth $1,837,000 after purchasing an additional 7,134 shares during the last quarter. Creative Planning boosted its position in Edwards Lifesciences by 1.7% in the fourth quarter. Creative Planning now owns 33,354 shares of the medical research company’s stock worth $3,759,000 after purchasing an additional 573 shares during the last quarter. National Pension Service boosted its position in Edwards Lifesciences by 1.2% in the fourth quarter. National Pension Service now owns 221,581 shares of the medical research company’s stock worth $24,974,000 after purchasing an additional 2,549 shares during the last quarter. Finally, Bank of Montreal Can boosted its position in Edwards Lifesciences by 44.2% in the fourth quarter. Bank of Montreal Can now owns 235,908 shares of the medical research company’s stock worth $26,588,000 after purchasing an additional 72,308 shares during the last quarter. 81.61% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have recently weighed in on EW. Canaccord Genuity restated a “buy” rating and set a $155.00 price target on shares of Edwards Lifesciences in a report on Sunday, October 8th. Cowen restated a “buy” rating and set a $135.00 price target on shares of Edwards Lifesciences in a report on Thursday, October 12th. Barclays reduced their price target on Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating for the company in a report on Wednesday, October 25th. JPMorgan Chase & Co. downgraded Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Finally, Deutsche Bank reduced their price target on Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating for the company in a report on Thursday, October 26th. Six investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $129.57.

COPYRIGHT VIOLATION NOTICE: “Edwards Lifesciences Corp (EW) VP Larry L. Wood Sells 6,300 Shares” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://ledgergazette.com/2018/01/18/edwards-lifesciences-corp-ew-vp-larry-l-wood-sells-6300-shares.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply